Managing the unpredictable symptoms of indolent systemic mastocytosis prompted a search for answers and community.

We recently compiled a list of the Why These 15 Stocks Are Skyrocketing in 2025. In this article, we are going to take a look ...

Piper Sandler updated their financial outlook for Blueprint Medicines (NASDAQ:BPMC), increasing the price target on the ...

TL-895 is under clinical development by Telios Pharma and currently in Phase II for Systemic Mastocytosis. According to GlobalData, Phase II drugs for Systemic Mastocytosis have a 64% phase transition ...

WALTHAM, Mass. and BOULDER, Colo., Jan. 30, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: COGT), a biotechnology company focused on ...

Despite a 15% drop in the SPDR S&P Biotech ETF, insider buying presents opportunities. Read why these small and mid-cap ...

Jeffrey W. Albers, a director at Blueprint Medicines Corp (NASDAQ:BPMC), recently executed significant stock transactions, ...

Leerink Partners analyst Thomas Smith has reiterated their neutral stance on ALLK stock, giving a Hold rating on January 27.Invest with ...

Report top-line results during the second half of 2025 from the APEX trial. APEX is a registration-directed, global, ...

Bezuclastinib's upcoming data in July 2025 could be a game-changer for COGT, offering a lucrative investment opportunity. See ...

In a report released yesterday, Sam Slutsky from LifeSci Capital maintained a Hold rating on Allakos (ALLK – Research Report), with a price ...

BPMC stock rallies 18% on the company's optimistic 2025 outlook encompassing Ayvakit sales growth and pipeline progress.